MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Up 0.7% – Still a Buy?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)’s share price shot up 0.7% during trading on Tuesday . The stock traded as high as $1.5861 and last traded at $1.50. 1,222,219 shares changed hands during mid-day trading, an increase of 4% from the average session volume of 1,180,232 shares. The stock had previously closed at $1.49.

MAIA Biotechnology Stock Performance

The business has a 50-day moving average of $1.94 and a 200-day moving average of $1.58. The stock has a market capitalization of $57.99 million, a price-to-earnings ratio of -2.05 and a beta of -0.04.

Insider Transactions at MAIA Biotechnology

In related news, Director Stan Smith acquired 57,189 shares of the stock in a transaction that occurred on Monday, December 22nd. The stock was purchased at an average price of $1.22 per share, with a total value of $69,770.58. Following the transaction, the director owned 1,421,478 shares of the company’s stock, valued at approximately $1,734,203.16. This trade represents a 4.19% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Steven M. Chaouki bought 40,849 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The stock was bought at an average price of $1.22 per share, with a total value of $49,835.78. Following the acquisition, the director directly owned 151,873 shares in the company, valued at $185,285.06. The trade was a 36.79% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 179,737 shares of company stock worth $219,279. 32.32% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MAIA. Geode Capital Management LLC grew its stake in shares of MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after buying an additional 7,746 shares in the last quarter. Centric Wealth Management raised its holdings in shares of MAIA Biotechnology by 740.2% in the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock valued at $1,032,000 after buying an additional 505,150 shares during the period. Marshall Wace LLP acquired a new position in MAIA Biotechnology during the 2nd quarter worth about $29,000. Jane Street Group LLC acquired a new position in MAIA Biotechnology during the 2nd quarter worth about $52,000. Finally, Ritholtz Wealth Management purchased a new position in MAIA Biotechnology during the 4th quarter valued at about $35,000. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.